CzMA JEP Home page CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ
Journals - Article
CzMA JEP Home page News About Assocation Publishing Division Medical Journals Searching Supplements Catalogue
 
  Česky / Czech version Vnitř. Lék., 49, 2003, No. 3, p. 222 - 226
 
Plasminogen Activator Inhibitor (PAI-1), Ischaemic Heart Disease and Diabetes Mellitus 
Olexa P.1, Olexová M.2 

1IV. interná klinika Lekárskej fakulty UPJŠ a Fakultnej nemocnice L. Pasteura, Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, Ph.D.2Oddelenie klinickej imunológie a alergológie Fakultnej nemocnice L. Pasteura, Košice, Slovenská republika, prednosta prim. MUDr. Jana Kiseľová
 


Summary:

       The classic risk factors can only in part explain the increased incidence and extent of coronary artery disease. Plasminogen activator inhibitor type-1 (PAI-1), the main human regulator of endogenous fibrinolysis, is considered to be an important cardiovascular risk factor. The article discuss the current knowledge of the PAI-1 importance and role in the in the pathogenesis of atherosclerosis and mechanisms of its synthesis predominantly in patients with coronary artery disease associated with diabetes mellitus type 2. It explaines contributions of PAI-1 to the pathophysiologic links between diabetes mellitus and cardiovascular diseases and shows current therapeutic interventions normalising PAI-1 activity, their beneficial effect on prognosis and course of coronary artery disease.

        Key words: Plasminogen activator inhibitor type-1 (PAI-1) - Atherogenesis - Diabetes mellitus - Hyperinsulinaemia
       

Order this issue

  BACK TO CONTENTS  
 
 
| HOME PAGE | CODE PAGE | CZECH VERSION |
©  1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o.
WEBMASTER